PURPOSE. To test whether a diet supplemented with coenzyme Q10 (CoQ 10 ) ameliorates glutamate excitotoxicity and oxidative stress-mediated retinal ganglion cell (RGC) degeneration by preventing mitochondrial alterations in the retina of glaucomatous DBA/2J mice.
G laucoma is the leading cause of irreversible blindness and affects 70 million people worldwide. 1, 2 Although elevated IOP is an important risk factor for optic nerve (ON) degeneration and retinal ganglion cell (RGC) death in glaucoma, lowering IOP is not always effective for preserving visual function in patients. 1, 2 Glutamate excitotoxicity and oxidative stress have been implicated as important pathophysiological mechanisms in mitochondrial dysfunction-mediated glaucomatous neurodegeneration. [3] [4] [5] [6] [7] [8] [9] [10] Increasing evidence indicates that glutamate excitotoxicity and oxidative stress are associated with mitochondrial DNA (mtDNA) alteration or DNA oxidation-related mitochondrial dysfunction in retinal neurodegeneration, including glaucoma. 4, 8, [11] [12] [13] Mitochondrial transcription factor A (Tfam, also as known as mtTFA), a nucleus-encoded DNA-binding protein in mitochondria, has an important role in mitochondrial gene expression and mtDNA maintenance and therefore is essential for oxidative phosphorylation (OXPHOS)-mediated adenosine triphosphate (ATP) synthesis. 8, [14] [15] [16] [17] Mice lacking Tfam have impairment of mtDNA transcription and loss of mtDNA, leading to bioenergetics dysfunction and embryonic lethality. 14 In contrast, overexpression of Tfam mediates delayed neuronal death following transient forebrain ischemia in mice. [18] [19] [20] Importantly, emerging evidence indicates that acute IOP elevation significantly increased Tfam/OXPHOS complex IV protein expression in the early neurodegeneration of ischemic rat retina, suggesting that these responses may support endoge-nous repair mechanisms for elevated IOP-induced mtDNA alteration. 8 Coenzyme Q10 (CoQ 10 ), an essential cofactor of the electron transport chain, acts by maintaining the mitochondrial membrane potential, supporting ATP synthesis and inhibiting reactive oxygen species generation for protecting neuronal cells against oxidative stress in neurodegenerative diseases. [21] [22] [23] [24] [25] Previous studies demonstrated that CoQ 10 protected retinal neurons against kainate-induced apoptotic injury 26 and against hydrogen peroxide-induced oxidative stress in vitro and N-methyl-D-aspartate-induced glutamate excitotoxicity in vivo. 27 Moreover, CoQ 10 prevented retinal damage caused by acute high IOP-induced transient ischemic injury. 28, 29 Of interest, the level of CoQ 10 in the human retina can decline by approximately 40% with age, 30 suggesting the possibility that this decline in CoQ 10 may be associated with age-related glaucomatous neurodegeneration.
Herein, we tested whether a diet supplemented with CoQ 10 ameliorates glutamate excitotoxicity and oxidative stressmediated RGC and axon degeneration in a mouse model of glaucoma. We also assessed whether CoQ 10 prevents mitochondrial alteration by preserving mtDNA content and Tfam/ OXPHOS complex IV protein expression in the retina of the mouse model.
METHODS Animals
Adult 4-month-old female DBA/2J and DBA/2J-Gpnmb þ (D2-Gpnmb þ ) mice (The Jackson Laboratory, Bar Harbor, ME) 31 were housed in covered cages, fed with CoQ 10 or a control diet daily for 6 months as reported below, and kept on a 12-hour light and 12-hour dark cycle. All procedures described were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and under protocols approved by the Institutional Animal Care and Use Committee at the University of California, San Diego.
CoQ 10 Treatment
Coenzyme Q10 was purchased from Kaneka Nutrients (Pasadena, TX). An AIN-93G purified control diet and a diet supplemented with CoQ 10 were formulated by Harlan Laboratories (Madison, WI). The following four groups of mice were studied: D2-Gpnmb þ mice treated with the control diet (n ¼ 25), DBA/2J mice treated with the control diet (n ¼ 70), D2-Gpnmb þ mice treated with the 1% CoQ 10 diet (vol/vol) (which equals a daily dose of 1600-2000 mg/kg body weight in mice weighing 25-30 g) (n ¼ 25), and DBA/2J mice treated with the 1% CoQ 10 diet (n ¼ 80). 32 To examine a daily dose for CoQ 10 , the amount of food taken by the mice was measured by weighing pelleted mouse chow that has 1% CoQ 10 , and then the actual dose of CoQ 10 that the mouse received was calculated.
IOP Measurement
The IOP elevation onset typically occurs between age 5 and 7 months, and IOP-linked ON axon loss is well advanced by age 10 months. 31, 33, 34 The DBA/2J and nonglaucomatous D2-Gpnmb þ mice used in this study had a single IOP measurement at age 10 months (to confirm the development of spontaneous IOP elevation > 20 mm Hg). The IOP measurement was performed as described previously. [33] [34] [35] Briefly, after anesthesia with a mixture of ketamine (100 mg/kg, Ketaset; Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (9 mg/kg, TranquiVed; Vedeco, Inc., St. Joseph, MO), a sterilized and water-filled microneedle with an external diameter of 50 to 70 lm was used to cannulate the anterior chamber. The microneedle was then repositioned to minimize corneal deformation and to ensure that the eye remained in its normal position. The microneedle was connected to a pressure transducer (Blood Pressure Transducer; WPI, Sarasota, FL), which relayed its signal to a bridge amplifier (Quad Bridge; ADInstruments, Castle Hill, New South Wales, Australia). The amplifier was connected to an analog to digital converter (Power Laboratory; ADInstruments) and a computer (G4 Macintosh; Apple Computer, Inc., Cupertino, CA).
Tissue Preparation
Mice were anesthetized with an intraperitoneal injection of a mixture of ketamine (100 mg/kg, Ketaset; Fort Dodge Animal Health) and xylazine (9 mg/kg, TranquiVed; Vedeco, Inc.) before cervical dislocation. For immunohistochemistry, the retinas were dissected from the choroids and fixed with 4% paraformaldehyde in PBS (pH 7.4) for 2 hours at 48C. After several washes in PBS, the retinas and ON heads (ONHs) were dehydrated through graded ethanols and embedded in polyester wax as previously described. 34 
Whole-Mount Immunohistochemical Analysis
Retinas from enucleated eyes were dissected as flattened whole mounts in 10-month-old glaucomatous DBA/2J and agematched nonglaucomatous D2-Gpnmb þ mice. The retinas were immersed in PBS containing 30% sucrose for 24 hours at 48C. The retinas were blocked in PBS containing 3% donkey serum, 1% BSA, 1% fish gelatin, 36, 37 and 0.1% Triton X-100 and then incubated with goat polyclonal anti-Brn3a antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), a specific maker for RGCs, 38 and guinea pig polyclonal anti-glial fibrillary acidic protein (GFAP) antibody (1:500; Advanced ImmunoChemical, Inc., Long Beach, CA) for 3 days at 48C. After several wash steps with PBS, the retinas were incubated with the secondary antibodies AlexaFluor 568 donkey anti-goat IgG antibody (1:100; Invitrogen, Carlsbad, CA) or Cy5-conjugated anti-guinea pig IgG antibody (1:100; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 24 hours and subsequently washed with PBS. The retinas were counterstained with Hoechst 33342 (1 lg/mL; Invitrogen) in PBS. Images were captured with a spinning disk confocal microscope (Olympus America, Inc., Center Valley, PA) equipped with a high-precision closed-loop XY stage and closed-loop Z control with commercial mosaic acquisition software (MicroBrightField; MBF Bioscience, Inc., Williston, VT).
Quantitative Analysis for RGC Counting
To count RGCs labeled with Brn3a, each retinal quadrant was divided into three zones by the central, middle, and peripheral retina (one-sixth, three-sixths, and five-sixths of the retinal radius, respectively). The RGC densities were measured in 24 distinct areas (two areas at the central, middle, and peripheral per retinal quadrant) per condition by two investigators (HK and SYK) in a masked fashion, and the scores were averaged (n ¼ 10 retinal flat mounts per group).
Western Blot Analysis
The retinas were immediately homogenized with mortar homogenizer in ristocetin-induced platelet agglutination lysis buffer (150 mM sodium chloride, 1 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 1 mM dithiothreitol, 0.5% sodium deoxycholate, and 50 mM Tris-cl [pH 7.6]) containing complete protease inhibitors (Roche Biochemicals, Indianapolis, IN). Ten micrograms of pooled retinal protein from each group (n ¼ 4 retinas per group) was separated by SDS-PAGE and electrotransferred to polyvinylidene difluoride membranes. The membrane was blocked with PBS-0.1% Tween 20 (PBST) containing 5% nonfat dry milk for 1 hour at room temperature and subsequently incubated with the primary antibodies for 16 hours at 48C. The primary antibodies were mouse monoclonal anti-GFAP antibody (1:3000; Sigma-Aldrich Corp., St. Louis, MO), rabbit polyclonal anti-N-methyl-D-aspartate receptor (NR) 1 antibody (1:1000; BD Pharmingen, San Diego, CA), rabbit polyclonal anti-NR2A antibody (1:500; Millipore, Billerica, MA), rabbit polyclonal anti-superoxide dismutase-2 (SOD2) antibody (1:5000; Santa Cruz Biotechnology), rabbit polyclonal antiheme oxygenase-1 (HO1) antibody (1:1000; Millipore), mouse monoclonal anti-actin antibody (1:5000; Millipore), rabbit polyclonal anti-Tfam antibody (1:3000; Santa Cruz Biotechnology), mouse monoclonal anti-total OXPHOS complex antibody (1:3000; Invitrogen), rabbit polyclonal anti-Porin antibody (1:1000; Calbiochem, La Jolla, CA), rabbit polyclonal anti-Bax antibody (1:500; Santa Cruz Biotechnology), and rabbit polyclonal anti-phosphorylated Bad (pBad) antibody (1:1000; Cell Signaling, Danvers, MA). After several washes in PBST, the membranes were incubated with peroxidase-conjugated goat anti-mouse IgG (1:5000; Bio-Rad, Hercules, CA), goat antirabbit IgG (1:5000; Bio-Rad), or donkey anti-goat IgG (1:5000; Bio-Rad) and developed by film using chemiluminescence detection (ECL Plus; GE Healthcare Bioscience, Piscataway, NJ). The scanned film images were analyzed by ImageJ (in the public domain at http://rsb.info.nih.gov/ij/), and the band intensities were normalized to the band intensity for actin.
Immunohistochemistry
Immunohistochemical staining was performed with 7-lm wax sections of ONHs as previously described. 34 To prevent nonspecific background, the sections were incubated in 1% BSA-PBS for 1 hour at room temperature before incubation with the primary antibodies for 16 hours at 48C. The primary antibodies were mouse monoclonal anti-neurofilament 68 (clone NR4, 1:500; Sigma-Aldrich Corp.) and guinea pig polyclonal anti-GFAP antibody (1:500; Advanced ImmunoChemical, Inc.). After several wash steps, the sections were incubated with the secondary antibodies AlexaFluor 488 dyeconjugated goat anti-mouse IgG (1:100; Invitrogen) and Cy5-conjugated anti-guinea pig IgG antibody (1:100; Jackson ImmunoResearch Laboratories, Inc.) for 2 hours at 48C and were subsequently washed with PBS. The sections were counterstained with Hoechst 33342 (1 lg/mL; Invitrogen) in PBS. Images were acquired with confocal microscopy (Olympus FluoView1000; Olympus, Tokyo, Japan).
Electron Microscopy
For conventional transmission electron microscopy (TEM), two eyes from each group were fixed via cardiac perfusion with solution at 378C in 2% paraformaldehyde and 2.5% glutaraldehyde (Ted Pella, Redding, CA) in 0.15 M sodium cacodylate (pH 7.4; Sigma-Aldrich Corp.) and placed in precooled fixative on ice for 1 hour. The ONs were dissected with 0.15 M sodium cacodylate plus 3 mM calcium chloride (pH 7.4) on ice and postfixed with 1% osmium tetroxide, 0.8% potassium ferrocyanide, and 3 mM calcium chloride in 0.1 M sodium cacodylate (pH 7.4) for 1 hour, and they were then washed with ice-cold distilled water, poststained with 2% uranyl acetate at 48C, dehydrated using graded ethanols, and embedded in Durcupan resin (Fluka, St. Louis, MO). Ultrathin (70 nm) sections were poststained with uranyl acetate and lead salts and evaluated with a JEOL 1200FX transmission electron microscope (JEOL USA, Inc., Peabody, MA) operated at 80 kV. Images were recorded on film at 38000 magnification. The negatives were digitized at 1800 dots per inch using a Nikon Cool scan system (Nikon, Melville, NY), giving an image size of 4033 3 6010-pixel array and a pixel resolution of 1.77 nm. For quantitative analysis, the number of axons was normalized to the total area occupied by axons in each image, which was measured using ImageJ (in the public domain at http://rsb.info.nih.gov/ij/).
Measurement of mtDNA Content
The mtDNA content of each sample was determined as described previously. 39 Briefly, total genomic DNA (gDNA) was isolated from retinas using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) as described in the manufacturer's protocol. For the measurement of relative mtDNA content, real-time PCR was carried out using an MX3000P real-time PCR system (Stratagene, La Jolla, CA). Total gDNA (10 ng) from each sample was amplified using iQTM SYBR Green Supermix (BioRad) and mitochondrial cytochrome B (CytB-F:
0 ) primers for 40 cycles (initial incubation at 958C for 10 minutes) and an additional 40 cycles (958C for 30 seconds, 558C for 30 seconds, and 728C for 20 seconds). Output data were obtained as Ct values, and the difference in mtDNA content among samples was calculated using the comparative Ct method. 40 The ActB gene was used to normalize the ratio between mtDNA and gDNA. The samples were run in triplicate for all experiments.
Statistical Analysis
Data are presented as means (SDs). Comparison of two or three experimental conditions was evaluated using the unpaired, two-tailed Student's t-test or one-way ANOVA and the Bonferroni t-test. P < 0.05 was considered statistically significant.
RESULTS
CoQ 10 Promotes RGC Survival in Glaucomatous DBA/2J Mice Preglaucomatous DBA/2J and age-matched nonglaucomatous control D2-Gpnmb þ mice at age 4 months were fed with either an unsupplemented control diet or a CoQ 10 (1%) diet daily for 6 months. We found that the daily dose for CoQ 10 per mouse was 33 (2) mg. To determine whether CoQ 10 induces changes in the body weight and IOP, we measured the body weight at age 4, 7, and 10 months and the IOP at age 10 months (Fig. 1A) . There was no significant change in the body weight between control and CoQ 10 -treated DBA/2J mice (Fig. 1B) . Consistent with our previous study, 34 the IOP peak was 23.1 (5.7) mm Hg among 10-month-old glaucomatous DBA/2J mice. However, there was no significant change in the IOP between control and CoQ 10 -treated DBA/2J mice (Fig. 1B) , indicating that the CoQ 10 diet did not change the IOP in glaucomatous DBA/2J mice. In addition, the mean IOP was 14.7 (5.7) mm Hg in 10-month-old D2-Gpnmb þ mice (Fig. 1B) . Because CoQ 10 protects RGCs against high IOP-induced transient ischemic injury 28 and other apoptotic insults, 26, 41 we determined RGC survival following CoQ 10 supplementation in glaucomatous DBA/2J mice by whole-mount immunohisto-chemistry using antibody raised against Brn3a. There was no significant change in RGC survival between control and CoQ 10 -treated 10-month-old D2-Gpnmb þ mice ( Supplementary Fig.  S1 , Supplementary Table S1 ). The mean RGC density per retina for each group is summarized in Supplementary Table S1 . The retinas from 10-month-old D2-Gpnmb þ mice treated with the control diet had a mean of 2754 (196) Table S1 ). Compared with D2-Gpnmb þ retinas treated with the control diet, glaucomatous DBA/2J mice treated with the control diet showed approximately 31% of RGC loss in the retinas (P < 0.05) ( Figs. 2A, 2B ; Supplementary Table S1 ). In contrast, CoQ 10 significantly promoted RGC survival by approximately 29% in glaucomatous DBA/2J mice (P < 0.05) ( Figs. 2A, 2B ; Supplementary Table S1 ). In addition, RGC loss was accompanied by activation of astroglia as indicated by significantly increased GFAP expression by 1.76 (0.44)-fold in the retinas of glaucomatous DBA/2J mice treated with the control diet compared with D2-Gpnmb þ mice treated with the control diet (P < 0.05) (Figs. 2A, 2C) . However, CoQ 10 significantly decreased GFAP expression by 1.42 (0.43)-fold in the retinas of glaucomatous DBA/2J mice (P < 0.05) (Figs. 2A,  2C ). To determine whether CoQ 10 preserves RGC axons in the glial lamina of the ONH in glaucomatous DBA/2J mice, we performed immunohistochemistry using antibodies raised against neurofilament, a marker for axons, and GFAP. The ONHs in glaucomatous DBA/2J mice treated with the control diet showed greater loss of axons in the glial lamina by decreasing neurofilament immunoreactivity compared with D2-Gpnmb þ mice treated with the control diet. However, the CoQ 10 diet partially restored neurofilament immunoreactivity in the glial lamina of glaucomatous DBA/2J mice (Figs. 3A, 3B ). In addition, the ONHs in glaucomatous DBA/2J mice treated with the control diet showed activation of astroglia in the glial lamina by increasing GFAP immunoreactivity and hypertrophic cell bodies compared with D2-Gpnmb þ mice treated with the control diet. However, the CoQ 10 diet partially restored GFAP immunoreactivity in the glial lamina of glaucomatous DBA/2J mice (Figs. 3A, 3B) .
Based on our in vivo results of axon preservation in the glial lamina, we sought to determine whether CoQ 10 preserves axonal integrity in the ON posterior to the myelination transition zone in glaucomatous DBA/2J mice by counting ON axons using conventional TEM analysis. The D2-Gpnmb þ mice treated with the control diet showed normal healthy morphology of myelinated axons in the ON (Fig. 4) . In contrast, glaucomatous DBA/2J mice treated with the control diet showed an absence of axons and the accumulation and disorganization of myelination in the ON. In addition, we found that abundant hypertrophic astrocyte processes were filled in the area of axon loss (Fig. 4) . Of interest, CoQ 10 treatment showed the preservation of axons and their myelination in the ON of glaucomatous DBA/2J mice (Fig. 4) . In good agreement with these results, quantitative analyses showed that the number of axons, normalized to the total area in each image, was significantly decreased approximately 62% in the ON of glaucomatous DBA/2J mice treated with the control diet compared with the ON of D2-Gpnmb þ mice treated with the control diet (0.15 [0.05] vs. 0.56 [0.03] lm 2 , P < 0.001) (Fig.  4) . A previous study 42 reported that glaucomatous DBA/2J mice showed greater than 50% loss of myelinated axons compared with young mice and old low-IOP mice. Although there was a difference in the axon density between these findings, it is possible that this difference might have resulted from the use of a counting method that only measured the healthy axons with intact myelination by electron microscopy analysis or from the great variability in the DBA model. Finally and most importantly, CoQ 10 significantly increased the number of axons and preserved myelination in the ON in glaucomatous DBA/2J mice (0.44 [0.08] lm 2 , P < 0.001) (Fig.  4) .
CoQ 10 Ameliorates Glutamate Excitotoxicity and Oxidative Stress in Glaucomatous Retina
Previous studies 6, 43 reported that the uncompetitive N-methyl-D-aspartate receptor antagonist memantine promoted RGC survival and that the antioxidant a-luminol reduced oxidative stress in the retinas of glaucomatous DBA/2J mice. In addition, CoQ 10 protects retinal cells or NT2/D1 neuronal precursor cells against glutamate excitotoxicity or oxidative stress. 27, 44 To determine whether CoQ 10 influences NRs and oxidative stress in the retinas of 10-month-old glaucomatous DBA/2J mice, relative changes in NR1, NR2A, SOD2, and HO1 protein expression were measured by Western blot analysis. Compared with the retinas of D2-Gpnmb þ mice treated with the control diet, NR1 and NR2A protein expression was significantly increased by 2.59 (0.21)-fold and 1.47 (0.12)-fold, respectively, in glaucomatous DBA/2J mice treated with the control diet (P < 0.05) (Fig. 5) . However, CoQ 10 significantly decreased NR1 and NR2A protein expression by 1.51 (0.14)-fold and 1.22 (0.11)-fold in glaucomatous DBA/2J mice (P < 0.05) (Fig. 5) , respectively. Compared with the retinas of D2-Gpnmb þ mice treated with the control diet, SOD2 and HO1 protein expression was significantly increased by 1.82 (0.43)-fold and 1.45 (0.12)-fold in glaucomatous DBA/2J mice treated with the control diet (P < 0.05) (Fig. 5) , respectively. However, CoQ 10 significantly decreased SOD2 and HO1 protein expression by 1.47 (0.34)-fold and 0.94 (0.20) fold in glaucomatous DBA/2J mice (P < 0.05) (Fig. 5) , respectively. 
CoQ 10 Decreases Bax but Increases pBad Expression in Glaucomatous Retina
To determine whether CoQ 10 modulates the apoptotic cell death pathway in glaucomatous DBA/2J mice, we performed Western blot analysis using antibodies raised against Bax and pBad. Bax protein expression was significantly increased by 2.08 (0.27)-fold in the retinas of glaucomatous DBA/2J mice treated with the control diet compared with D2-Gpnmb þ mice treated with the control diet (P < 0.05) (Fig. 6) . Compared with glaucomatous DBA/2J mice treated with the control diet, CoQ 10 significantly decreased Bax protein expression by 1.15 (0.09)-fold in glaucomatous DBA/2J mice (P < 0.05) (Fig. 6 ). In addition, pBad protein expression significantly increased by 2.51 (0.34)-fold in the retinas of glaucomatous DBA/2J mice treated with the control diet compared with D2-Gpnmb þ mice treated with the control diet (P < 0.05) (Fig. 6) . Compared with glaucomatous DBA/2J mice treated with the control diet, CoQ 10 significantly increased Bax protein expression by 3.67 (0.21)-fold in the retinas of glaucomatous DBA/2J mice (P < 0.05) (Fig. 6 ).
CoQ 10 Preserves mtDNA Content and Tfam/ OXPHOS Complex IV Protein Expression in Glaucomatous Retina
Although mtDNA is particularly susceptible to glutamate excitotoxicity-induced oxidative stress, 45 it is unknown whether glutamate excitotoxicity and oxidative stress are associated with mtDNA alteration in the retinas of glaucomatous DBA/2J mice. To determine whether glutamate excitotoxicity and oxidative stress induced by IOP elevation alter mtDNA content and whether CoQ 10 preserves this alteration in the retinas of glaucomatous DBA/2J mice, the relative mtDNA content was measured by real-time PCR. The relative mtDNA content was slightly increased by 110% (20%), but there was no statistical significance in the retinas of glaucomatous DBA/ 2J mice treated with the control diet compared with D2-Gpnmb þ mice treated with the control diet (Fig. 7A) . However, CoQ 10 significantly decreased mtDNA content by 88% (13%) in the retinas of glaucomatous DBA/2J mice compared with D2-Gpnmb þ mice treated with the control diet (P < 0.05) (Fig.  7A) . To further determine whether glutamate excitotoxicity Note that abundant hypertrophic astrocyte processes were filled in the area of axon loss. However, CoQ 10 diet-treated glaucomatous DBA/2J mice showed partial preservation of axons and myelination in the ON. Quantitative analyses showed that the number of axons, normalized to the total area in each image, was significantly decreased in the ON of glaucomatous DBA/2J mice treated with the control diet (n ¼ 10 images) compared with the ON of D2-Gpnmb þ mice treated with the control diet (n ¼ 6 images). In contrast, CoQ 10 significantly increased the number of axons in the ON of glaucomatous DBA/2J mice (n ¼ 12 images). ***Significant at P < 0.001 compared with D2-Gpnmb þ mice treated with the control diet or glaucomatous DBA/2J mice treated with the control diet. Scale bars: 2 lm. and oxidative stress induced by IOP elevation alter Tfam/ OXPHOS complex IV protein expression and whether CoQ 10 preserves this alteration in glaucomatous DBA/2J mice, we performed Western blot analysis using antibodies raised against Tfam and OXPHOS complex protein. The Tfam and OXPHOS complex IV protein expression was significantly increased by 1.82 (0.35)-fold and 1.56 (0.31)-fold, respectively, in the retinas of glaucomatous DBA/2J mice treated with the control diet compared with D2-Gpnmb þ mice treated with the control diet (P < 0.05) (Fig. 7B) . Compared with glaucomatous DBA/2J mice treated with the control diet, CoQ 10 significantly decreased Tfam and OXPHOS complex IV protein expression by 1.38 (0.19)-fold and 0.98 (0.15)-fold, respectively, in glaucomatous DBA/2J mice (P < 0.05) (Fig. 7B) .
DISCUSSION
Coenzyme Q10 is a potent antioxidant and neurotherapeutic agent against oxidative stress in many neurodegenerative diseases, including Parkinson and Huntington diseas-FIGURE 5. The blockade of oxidative stress and glutamate excitotoxicity in glaucomatous DBA/2J mice treated with the CoQ 10 diet. The retinas of glaucomatous DBA/2J mice treated with the control diet significantly increased SOD2, HO1, NR1, and NR2A protein expression compared with D2-Gpnmb þ mice treated with the control diet. In contrast, the CoQ 10 diet significantly decreased SOD2, HO1, NR1, and NR2A protein expression in the retinas of glaucomatous DBA/2J mice. Values are means (SDs) (n ¼ 4 retinas per group). *Significant at P < 0.05 compared with D2-Gpnmb þ mice treated with the control diet or glaucomatous DBA/2J mice treated with the control diet.
es. 23, 32, [46] [47] [48] Of note, it has been reported that the level of CoQ 10 in the human retina declines with age, 30 raising the possibility that the decline in CoQ 10 level with aging may lead to increased vulnerability of RGCs in glaucomatous neurodegeneration due to a link between older age and the prevalence of glaucoma. 11 Moreover, growing evidence indicates that CoQ 10 is neuroprotective in retinal cells against pressure in vivo and in vitro, as well as against oxidative stress, excitotoxicity, and apoptotic radiation. 27, 28, 41, 49 The dose of CoQ 10 supplementation correlates well with the plasma CoQ 10 level: when administered in large doses, CoQ 10 was taken up by all tissues, including heart and brain mitochondria. 50 These findings suggest that CoQ 10 could also be taken up by the retina and lead to a beneficial effect in glaucomatous retina. Nevertheless, the effect of CoQ 10 and its protective mechanisms in glaucomatous neurodegeneration remain unknown.
In the present study, we found that a diet supplementation with CoQ 10 for 6 months significantly promoted RGC survival in glaucomatous DBA/2J mice. In addition, CoQ 10 not only preserved RGC axons in the ON but also blocked astroglial activation in the ONH of glaucomatous DBA/2J mice. These results indicate that CoQ 10 can ameliorate RGC survival and axon degeneration during glaucomatous neurodegeneration. Because astroglia or Müller cell activation coincides with RGC degeneration in the hypertensive retina of human, rat, and mouse 8, [51] [52] [53] [54] and with the glaucomatous retina or ONH of human, rat, and mouse, [55] [56] [57] our findings showing CoQ 10 -mediated inhibition of astroglial activation in the retina and ONH may reflect the possibility that CoQ 10 -mediated blockade of oxidative stress may indirectly reduce astroglial activation in the retina or ONH against elevated IOP-induced glaucomatous damage as a result of increased RGC survival. Regardless, it cannot be ruled out that CoQ 10 may also prevent glial activation by directly blocking oxidative stress in astroglia or Müller cells in glaucomatous retina and ONH. Future studies will be needed to determine whether CoQ 10 is also neuroprotective in glial cells in the retina or ONH against oxidative stress because oxidative stress has remarkably been linked to glial cell activation or reaction in the retina and ON. 8, [57] [58] [59] [60] [61] Glutamate excitotoxicity-mediated oxidative stress is considered one of the major causal factors for neuronal cell death in many neurodegenerative diseases, including glaucoma. [6] [7] [8] 29, [62] [63] [64] Emerging evidence indicates that glutamate excitotoxicity-mediated oxidative stress has been linked to mitochondrial dysfunction in retinal injury. 7, 8 In the present study, our findings demonstrated the first evidence to date that CoQ 10 significantly blocks the upregulation of NR1, NR2A, SOD2, and HO1 protein expression in the retina of glaucoma- tous DBA/2J mice, raising the possibility not only that glutamate excitotoxicity triggers oxidative stress but also that excessive oxidative stress may, in turn, lead to increased vulnerability of the retina by involving the upregulation of NRs in glaucomatous neurodegeneration. Therefore, we suggest that CoQ 10 has therapeutic potential for ameliorating glutamate excitotoxicity and oxidative stress-mediated glaucomatous neurodegeneration in the retina.
Consistent with our finding that CoQ 10 promoted RGC survival in glaucomatous DBA/2J mice, we observed that CoQ 10 significantly decreased Bax protein expression but increased pBad protein expression in the retina of glaucomatous DBA/2J mice. Bax is a proapoptotic member of the Bcl-2 family that is essential in many pathways of apoptosis 65, 66 and directly interacts with the component forming the mitochondrial permeability transition pore allowing proteins to escape from the mitochondria into the cytosol to initiate apoptosis. [67] [68] [69] Bax is counteracted by Bcl-xL, which forms heterodimers with dephosphorylation of Bad, which inactivates Bcl-xL, and pBad eliminates this dimerization, which activates BclxL. 70, 71 Collectively, our results suggest that CoQ 10 may promote RGC survival against the mitochondria-related apoptotic pathway in glaucomatous neurodegeneration by decreasing Bax protein expression and by increasing pBad protein expression. These results suggest that increased pBad expression may represent an endogenous repair mechanism against the apoptotic pathway and that CoQ 10 may contribute to the blockade of a Bax-mediated increase in mitochondrial membrane permeability or the promotion of mitochondrial homeostasis in glaucomatous neurodegeneration.
Alterations of mtDNA or OXPHOS induced by glutamate excitotoxicity and oxidative stress have been implicated in the pathogenesis of glaucoma. 9, 11, [72] [73] [74] [75] [76] [77] Tfam regulates mtDNA copy numbers in mammals, and the levels of Tfam correlate with the levels of mtDNA. 15, 78 Recent evidence suggests that Tfam/OXPHOS complex IV protein is rapidly increased in the early neurodegenerative events of ischemic retinal injury or neonatal hypoxic-ischemic brain injury, indicating that Tfam may contribute to an endogenous repair mechanism of injured retinal or brain neurons. 8, 79 Furthermore, recent studies 18,19 reported that overexpression of Tfam protects mitochondria against b-amyloid-induced oxidative damage in human SH-SY5Y neuroblastoma cells and ameliorates delayed neuronal cell death in the hippocampus following transient forebrain ischemia in mice. On the other hand, impaired mtDNA transcription and mtDNA loss are triggered in mice lacking Tfam, leading to mitochondrial bioenergetic dysfunctionmediated embryonic lethality. 14 However, it is unknown whether glutamate excitotoxicity and oxidative stress induced by IOP elevation alter Tfam/OXPHOS complex IV protein expression in the retina or whether CoQ 10 blocks this alteration of Tfam/OXPHOS complex IV protein expression against glaucomatous neurodegeneration. We found that elevated IOP significantly triggered an increase in Tfam/OXPHOS complex IV protein expression in the retina of glaucomatous DBA/2J mice. However, CoQ 10 preserved mtDNA content and Tfam/OXPHOS complex IV protein expression in the retina of glaucomatous DBA/2J mice. Consistent with these results, our previous findings demonstrated that acute IOP elevation triggered glutamate excitotoxicity and oxidative stress, as well as the upregulation of Tfam protein expression in early retinal neurodegeneration. 8 Collectively, these results suggest that increasing Tfam/OXPHOS complex IV protein expression may be an important mtDNArelated endogenous compensatory mechanism in mitochondria against glutamate excitotoxicity and oxidative stress in glaucomatous neurodegeneration. Furthermore, CoQ 10 -mediated preservation of mtDNA content and Tfam/OXPHOS complex IV protein expression may provide a potential mechanism for protecting RGCs against glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in glaucomatous neurodegeneration.
In conclusion, these results provide the first direct evidence to date that CoQ 10 promotes RGC survival by inhibiting oxidative stress, glutamate excitotoxicity, and activation of the Bax and Bad-mediated apoptotic pathway and by preserving mtDNA content and Tfam/OXPHOS complex IV protein expression in glaucomatous DBA/2J mice. Based on these observations, our findings suggest that CoQ 10 may be a promising therapeutic strategy for ameliorating glutamate excitotoxicity and oxidative stress in glaucomatous neurodegeneration.
